These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

906 related items for PubMed ID: 16005483

  • 1. Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene.
    Bashir A, Mak YT, Sankaralingam S, Cheung J, McGowan NW, Grigoriadis AE, Fogelman I, Hampson G.
    Steroids; 2005 Dec 01; 70(13):847-55. PubMed ID: 16005483
    [Abstract] [Full Text] [Related]

  • 2. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism.
    Stilgren LS, Rettmer E, Eriksen EF, Hegedüs L, Beck-Nielsen H, Abrahamsen B.
    Bone; 2004 Jul 01; 35(1):256-65. PubMed ID: 15207766
    [Abstract] [Full Text] [Related]

  • 3. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones.
    Ikeda T, Utsuyama M, Hirokawa K.
    J Bone Miner Res; 2001 Aug 01; 16(8):1416-25. PubMed ID: 11499864
    [Abstract] [Full Text] [Related]

  • 4. Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins.
    Abrahamsen B, Hjelmborg JV, Kostenuik P, Stilgren LS, Kyvik K, Adamu S, Brixen K, Langdahl BL.
    Bone; 2005 Apr 01; 36(4):727-35. PubMed ID: 15781001
    [Abstract] [Full Text] [Related]

  • 5. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.
    García-Valdecasas-Campelo E, González-Reimers E, Santolaria-Fernández F, De la Vega-Prieto MJ, Milena-Abril A, Sánchez-Pérez MJ, Martínez-Riera A, Gómez-Rodríguez Mde L.
    Alcohol Alcohol; 2006 Apr 01; 41(3):261-6. PubMed ID: 16476762
    [Abstract] [Full Text] [Related]

  • 6. The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone.
    Han KO, Choi JT, Choi HA, Moon IG, Yim CH, Park WK, Yoon HK, Han IK.
    Clin Endocrinol (Oxf); 2005 Mar 01; 62(3):349-53. PubMed ID: 15730418
    [Abstract] [Full Text] [Related]

  • 7. Synthesis of osteoprotegerin and RANKL by megakaryocytes is modulated by oestrogen.
    Bord S, Frith E, Ireland DC, Scott MA, Craig JI, Compston JE.
    Br J Haematol; 2004 Jul 01; 126(2):244-51. PubMed ID: 15238146
    [Abstract] [Full Text] [Related]

  • 8. The ratio of messenger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis.
    Fazzalari NL, Kuliwaba JS, Atkins GJ, Forwood MR, Findlay DM.
    J Bone Miner Res; 2001 Jun 01; 16(6):1015-27. PubMed ID: 11393778
    [Abstract] [Full Text] [Related]

  • 9. Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women.
    Kim JG, Kim JH, Lee DO, Kim H, Kim JY, Suh CS, Kim SH, Choi YM.
    Menopause; 2008 Jun 01; 15(2):357-62. PubMed ID: 17925661
    [Abstract] [Full Text] [Related]

  • 10. Increased expression of IL-6 and RANK mRNA in human trabecular bone from fragility fracture of the femoral neck.
    Tsangari H, Findlay DM, Kuliwaba JS, Atkins GJ, Fazzalari NL.
    Bone; 2004 Jul 01; 35(1):334-42. PubMed ID: 15207775
    [Abstract] [Full Text] [Related]

  • 11. Megakaryocytes modulate osteoblast synthesis of type-l collagen, osteoprotegerin, and RANKL.
    Bord S, Frith E, Ireland DC, Scott MA, Craig JI, Compston JE.
    Bone; 2005 May 01; 36(5):812-9. PubMed ID: 15794927
    [Abstract] [Full Text] [Related]

  • 12. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women.
    Kim JG, Kim JH, Kim JY, Ku SY, Jee BC, Suh CS, Kim SH, Choi YM.
    Menopause; 2007 May 01; 14(5):913-8. PubMed ID: 17667143
    [Abstract] [Full Text] [Related]

  • 13. The RANKL/OPG system and bone mineral density in patients with chronic liver disease.
    Moschen AR, Kaser A, Stadlmann S, Millonig G, Kaser S, Mühllechner P, Habior A, Graziadei I, Vogel W, Tilg H.
    J Hepatol; 2005 Dec 01; 43(6):973-83. PubMed ID: 16143421
    [Abstract] [Full Text] [Related]

  • 14. Genetic polymorphisms of OPG, RANK, and ESR1 and bone mineral density in Korean postmenopausal women.
    Choi JY, Shin A, Park SK, Chung HW, Cho SI, Shin CS, Kim H, Lee KM, Lee KH, Kang C, Cho DY, Kang D.
    Calcif Tissue Int; 2005 Sep 01; 77(3):152-9. PubMed ID: 16151677
    [Abstract] [Full Text] [Related]

  • 15. Increased RANKL/OPG mRNA ratio in iliac bone biopsies from women with hip fractures.
    Abdallah BM, Stilgren LS, Nissen N, Kassem M, Jørgensen HR, Abrahamsen B.
    Calcif Tissue Int; 2005 Feb 01; 76(2):90-7. PubMed ID: 15570403
    [Abstract] [Full Text] [Related]

  • 16. Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation.
    Koyama H, Nakade O, Takada Y, Kaku T, Lau KH.
    J Bone Miner Res; 2002 Jul 01; 17(7):1219-29. PubMed ID: 12096835
    [Abstract] [Full Text] [Related]

  • 17. Osteoprotegerin (OPG)/RANK-L system in juvenile idiopathic arthritis: is there a potential modulating role for OPG/RANK-L in bone injury?
    Masi L, Simonini G, Piscitelli E, Del Monte F, Giani T, Cimaz R, Vierucci S, Brandi ML, Falcini F.
    J Rheumatol; 2004 May 01; 31(5):986-91. PubMed ID: 15124262
    [Abstract] [Full Text] [Related]

  • 18. Osteoprotegerin and RANKL in alcoholic liver cirrhosis.
    Fábrega E, Orive A, García-Suarez C, García-Unzueta M, Antonio Amado J, Pons-Romero F.
    Liver Int; 2005 Apr 01; 25(2):305-10. PubMed ID: 15780054
    [Abstract] [Full Text] [Related]

  • 19. Effects of polyethylene and TiAlV wear particles on expression of RANK, RANKL and OPG mRNA.
    Baumann B, Rader CP, Seufert J, Nöth U, Rolf O, Eulert J, Jakob F.
    Acta Orthop Scand; 2004 Jun 01; 75(3):295-302. PubMed ID: 15260421
    [Abstract] [Full Text] [Related]

  • 20. Changes in osteoprotegerin/RANKL system, bone mineral density, and bone biochemicals markers in patients with recent spinal cord injury.
    Maïmoun L, Couret I, Mariano-Goulart D, Dupuy AM, Micallef JP, Peruchon E, Ohanna F, Cristol JP, Rossi M, Leroux JL.
    Calcif Tissue Int; 2005 Jun 01; 76(6):404-11. PubMed ID: 15812577
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.